Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Prevenar 13 in Healthy Adults 18-49 Years in India
NCT05329259Phase 4Completed
- Sponsor
- Pfizer
- Start
- Oct 2022
- Primary completion
- Nov 2022
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pneumococcal 13-valent conjugate vaccine in pneumococcal disease, sponsored by Pfizer. Primary endpoints: Percentage of Participants With Prompted Local Reactions at 7 days, Percentage of Participants With Prompted Systemic Events at 7 days and 2 more. Started Oct 2022; status: completed.
02
Drugs
pneumococcal 13-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT05329259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05329259.